This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -35.29% and 90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Guardant Health (GH) delivered earnings and revenue surprises of 21.24% and 9.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 0.00% and 43.33%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Cardiff Oncology (CRDF) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardiff Oncology (CRDF) Stock Jumps 7%: Will It Continue to Soar?
by Zacks Equity Research
Cardiff Oncology (CRDF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -13.33% and 4.62%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oncology Space Gains Momentum in 2021: 5 Stocks to Focus on
by Debanjana Dey
Oncology stocks like OncoCyte (OCX), PerkinElmer (PKI), Catalent (CTLT), Cardiff Oncology (CRDF) and NovoCure (NVCR) are expected to continue their run over the next few months.
Are Options Traders Betting on a Big Move in Cardiff Oncology (CRDF) Stock?
by Zacks Equity Research
Investors need to pay close attention to Cardiff Oncology (CRDF) stock based on the movements in the options market lately.
Cardiff Oncology (CRDF) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 0.00% and -4.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Cardiff Oncology (CRDF): Can Its 10.3% Jump Turn into More Strength?
by Zacks Equity Research
Cardiff Oncology (CRDF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Rising P/E: An Overlooked Way to Pick 5 Winning Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Rising P/E: An Overlooked Strategy to Pick Winning Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Cardiff Oncology (CRDF) Stock Jumps 11.3%: Will It Continue to Soar?
by Zacks Equity Research
Cardiff Oncology (CRDF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Cardiff Oncology (CRDF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Cardiff Oncology (CRDF) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Cardiff Oncology (CRDF) stock based on the movements in the options market lately.
Implied Volatility Surging for Cardiff Oncology (CRDF) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Cardiff Oncology (CRDF) stock based on the movements in the options market lately.